Therapeutic use and formulation
US6297286A · kind A · utility
24Cited by
5References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 8, 2000 |
| Grant date | Oct 2, 2001 |
| Priority date | — |
| Expiry date | Nov 8, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Substantially single-enantiomer(-)-tramadol, and its metabolites and structural and/or functional analogues, are useful for the prevention and/or treatment of one or more symptoms selected from nausea, vomiting, dizziness, blurred vision, drowsiness, somnolence, hallucinations, respiratory depression, constipation and euphoria. In particular, substantially single enantiomer (-)-tramadol, and its o-desmethyl metabolite, have been found to be potent anti-emetics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.